Regeneron to seek EUA for lower dose of Covid-19 mAb cocktail as new trial shows major drop in risk of hospitalization or death
The success of monoclonal antibody (mAb) cocktails in keeping people with Covid-19 out of the hospital continued Tuesday, with Regeneron announcing that even a lower-than-authorized dose of its combination of mAbs reduced hospitalization or death by 70% in non-hospitalized Covid-19 patients.
“We will rapidly discuss the new data with regulatory authorities and request that the 1,200 mg dose be added to the U.S. Emergency Use Authorization, in order for the anticipated REGEN-COV supply to be available to treat even more patients,” George Yancopoulos, president and CSO of Regeneron, said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.